Table 5. Comparison of baseline clinical characteristics between survivors and non-survivors.
| Parameters | survivor (n = 42) | Non-survivor (n = 30) | P value (Cox univariate) | P value (Cox multivariate) | RR (95% CI) |
|---|---|---|---|---|---|
| Age (yr) | 41.5 (17–60) | 44.5 (22–79) | 0.019 | ||
| Male, n (%) | 40 (95.2%) | 25 (83.3%) | 0.389 | ||
| Alanine aminotransferase (IU/L) | 169 (21–1499) | 94 (18–2495) | 0.187 | ||
| Albumin (g/L) | 29.5 (19–45) | 29 (23–41) | 0.803 | ||
| Blood Urea Nitrogen (mmol/L) | 4.2 (1.9–12.1) | 6.4 (2.2–15.5) | 0.039 | ||
| Sodium (mmol/L) | 136 (126–144) | 134 (122–143) | 0.091 | ||
| Total bilirubin (mg/dL) | 17.3 (10.1–30.9) | 24.7 (12.8–42.6) | < 0.001 | 0.001 | 1.08(1.03–1.12) |
| Creatinine (mg/dL) | 1.0 (0.7–1.8) | 1.1 (0.7–3.7) | 0.105 | ||
| International normalized ratio (INR) | 1.8 (1.5–2.7) | 2.0 (1.5–3.4) | 0.015 | ||
| White Blood Cells (109/L) | 6.3 (1.7–15.4) | 7.1 (2.5–17.5) | 0.057 | ||
| HBV DNA (Log10 copies/ml) | 4.8 (1.6–8.1) | 3.2 (1.6–9.5) | 0.224 | ||
| Cirrhosis, n (%) | 25 (59.5%) | 19 (63.3%) | 0.744 | ||
| CTP scoring | 11 (9–13) | 11.5 (9–13) | 0.062 | ||
| MELD scoring | 24 (18–30) | 27 (21–42) | 0.001 | ||
| MELD-Na scoring | 24 (4–37) | 33 (14–48) | < 0.001 | ||
| Cystatin C (mg/L) | 1.36 (0.81–2.91) | 1.92 (1.21–91) | < 0.001 | 0.001 | 2.54(1.59–4.08) |
| Ascites, n (%) | 32 (76.2%) | 24 (80%) | 0.701 | ||
| Spontaneous bacterial peritonitis, n (%) | 8 (19.1%) | 6 (20%) | 0.920 | ||
| Hepatic encephalopathy (I–II), n (%) | 6 (14.3%) | 6 (20%) | 0.521 | ||
| Acute kidney injury, n (%) * | 1 (2.4%) | 4 (13.3%) | 0.153 | ||
| Antiviral therapy, n (%) | 42 (100%) | 28 (93%) | 0.090 |
All data were present as median (min-max) or number (%).
* Fisher’s Exact Test